Vera Therapeutics Inc Rises on Board Appointment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 02 Dec 25
Source: globenewswire
Vera Therapeutics Inc shares rose by 16.30%, crossing above the 5-day SMA. This increase follows the appointment of Jim Meyers, a seasoned biopharma executive, to the Board of Directors. Meyers' extensive experience is expected to guide the company through the anticipated launch of atacicept, a dual BAFF/APRIL inhibitor aimed at treating IgA nephropathy and other autoimmune diseases. The strategic addition of Meyers is seen as a pivotal moment for Vera Therapeutics as it prepares to transform treatment standards in the autoimmune sector.
Analyst Views on VERA
Wall Street analysts forecast VERA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VERA is 74.08 USD with a low forecast of 33.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 45.110
Low
33.00
Averages
74.08
High
100.00
Current: 45.110
Low
33.00
Averages
74.08
High
100.00
About VERA
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
